公开(公告)号：US20250011285A1

公开(公告)日：2025-01-09

申请号：US18708157

申请日：2022-11-09

Applicant: ORION CORPORATION

Inventor： David DIN BELLE ,  Pekka PIETIKÄINEN ,  Petteri RUMMAKKO ,  Gerd WOHLFAHRT

IPC: C07D209/44 ,  A61K31/4035 ,  A61K31/423 ,  A61K31/454 ,  A61K31/4709 ,  A61K45/06 ,  C07D209/46 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D413/06 ,  C07D413/14

Abstract: The present invention relates to a compound of formula (I) wherein A, B, R1, R2, R3, R4 and R5 are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, for example androgen receptor or estrogen receptor, dependent diseases and conditions, such as cancer including prostate cancer and breast cancer.

公开(公告)号：US20240246899A1

公开(公告)日：2024-07-25

申请号：US18428938

申请日：2024-01-31

Applicant: Celgene Corporation

Inventor： John F. Traverse ,  Michael J. Zacuto ,  Weihong Zhang ,  Kirsten Faye Johnson ,  Maryll E. Geherty ,  Christopher Marton

IPC: C07C231/18 ,  C07C67/313 ,  C07C231/02 ,  C07C231/12 ,  C07C237/06 ,  C07C237/12 ,  C07C273/18 ,  C07C275/24 ,  C07C275/70 ,  C07D209/46

CPC classification number: C07C231/18 ,  C07C67/313 ,  C07C231/02 ,  C07C231/12 ,  C07C237/06 ,  C07C237/12 ,  C07C273/1809 ,  C07C275/24 ,  C07C275/70 ,  C07D209/46

Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

公开(公告)号：US11998901B2

公开(公告)日：2024-06-04

申请号：US17676078

申请日：2022-02-18

Applicant: INSTITUTE FOR BASIC SCIENCE ,  KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Sukbok Chang ,  Seung Youn Hong ,  Yoon Su Park ,  Yeongyu Hwang ,  Yeong Bum Kim

IPC: C07D207/267 ,  B01J31/22 ,  C07D209/34 ,  C07D209/46 ,  C07D209/52 ,  C07D209/54 ,  C07D209/56 ,  C07D209/70 ,  C07D403/04 ,  C07D405/04 ,  C07D409/04 ,  C07F15/06 ,  C07F17/02 ,  C07J43/00

CPC classification number: B01J31/2295 ,  C07D207/267 ,  C07D209/46 ,  C07D209/52 ,  C07D209/54 ,  C07D209/56 ,  C07D209/70 ,  C07D403/04 ,  C07D405/04 ,  C07D409/04 ,  C07F17/02 ,  C07J43/003 ,  B01J2231/60

Abstract: The present invention relates to a novel metal complex, a method for producing same, and a method for producing a gamma-lactam compound using same, and the metal complex according to the present invention is used as a catalyst for producing a gamma-lactam compound and can efficiently produce a gamma-lactam compound with an excellent yield and excellent selectivity.

公开(公告)号：US20230348456A1

公开(公告)日：2023-11-02

申请号：US18140302

申请日：2023-04-27

Applicant: Repare Therapeutics Inc.

Inventor： Janek SZYCHOWSKI ,  Bingcan LIU ,  Evelyne DIETRICH ,  Alexander PERRYMAN ,  Sheldon N. CRANE ,  Vouy Linh TRUONG ,  Abbas ABDOLI ,  Alexanne BOUCHARD

IPC: C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D491/107 ,  C07D209/46 ,  C07D493/08 ,  C07D411/14

CPC classification number: C07D417/14 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D491/107 ,  C07D209/46 ,  C07D493/08 ,  C07D411/14

Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

公开(公告)号：US11731953B2

公开(公告)日：2023-08-22

申请号：US17354203

申请日：2021-06-22

Applicant: PMV Pharmaceuticals, Inc.

Inventor： Binh Vu ,  Romyr Dominique ,  Hongju Li ,  Bruce Fahr ,  Yi Chen

IPC: C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D209/46 ,  C07D209/94 ,  C07D209/34

CPC classification number: C07D401/04 ,  C07D209/34 ,  C07D209/46 ,  C07D209/94 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04

Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

公开(公告)号：US11701373B2

公开(公告)日：2023-07-18

申请号：US17307138

申请日：2021-05-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  T. G. Murali Dhar ,  Hai-Yun Xiao ,  John L. Gilmore ,  Michael G. Yang ,  Zili Xiao ,  David Marcoux

IPC: A61K31/695 ,  C07F7/08 ,  A61K31/135 ,  C07D215/14 ,  C07D241/04 ,  C07C323/29 ,  C07C251/38 ,  C07C251/42 ,  C07C251/44 ,  C07D209/46 ,  C07D213/38 ,  C07C275/26 ,  C07C217/74 ,  C07C323/25 ,  C07C235/46 ,  C07F9/54 ,  C07F9/572 ,  C07F9/09 ,  C07C215/42 ,  C07C217/52 ,  C07C217/58 ,  C07C219/24 ,  C07C233/41 ,  C07C233/65 ,  C07C251/50 ,  C07C251/52 ,  C07C251/54 ,  C07C271/34 ,  C07C317/28 ,  C07C317/32 ,  C07C321/16 ,  C07C321/22 ,  C07C321/28 ,  C07D213/32 ,  C07D213/69 ,  C07D213/70 ,  C07D215/12 ,  C07D217/24 ,  C07D231/12 ,  C07D231/20 ,  C07D239/26 ,  C07D241/12 ,  C07D277/24 ,  C07D305/08 ,  C07D309/06 ,  C07D309/12 ,  C07D311/58 ,  C07D311/76 ,  C07D319/20 ,  C07D333/16 ,  C07F9/117 ,  C07F9/62 ,  C07F9/6503 ,  C07F9/6509 ,  C07F9/655 ,  C07F9/6553 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K31/166 ,  A61K31/17 ,  A61K31/222 ,  A61K31/24 ,  A61K31/27 ,  A61K31/337 ,  A61K31/351 ,  A61K31/352 ,  A61K31/381 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/661

CPC classification number: A61K31/695 ,  A61K31/135 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K31/166 ,  A61K31/17 ,  A61K31/222 ,  A61K31/24 ,  A61K31/27 ,  A61K31/337 ,  A61K31/351 ,  A61K31/352 ,  A61K31/381 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/661 ,  C07C215/42 ,  C07C217/52 ,  C07C217/58 ,  C07C217/74 ,  C07C219/24 ,  C07C233/41 ,  C07C233/65 ,  C07C235/46 ,  C07C251/38 ,  C07C251/42 ,  C07C251/44 ,  C07C251/50 ,  C07C251/52 ,  C07C251/54 ,  C07C271/34 ,  C07C275/26 ,  C07C317/28 ,  C07C317/32 ,  C07C321/16 ,  C07C321/22 ,  C07C321/28 ,  C07C323/25 ,  C07C323/29 ,  C07D209/46 ,  C07D213/32 ,  C07D213/38 ,  C07D213/69 ,  C07D213/70 ,  C07D215/12 ,  C07D215/14 ,  C07D217/24 ,  C07D231/12 ,  C07D231/20 ,  C07D239/26 ,  C07D241/04 ,  C07D241/12 ,  C07D277/24 ,  C07D305/08 ,  C07D309/06 ,  C07D309/12 ,  C07D311/58 ,  C07D311/76 ,  C07D319/20 ,  C07D333/16 ,  C07F7/08 ,  C07F7/081 ,  C07F9/091 ,  C07F9/117 ,  C07F9/5442 ,  C07F9/5728 ,  C07F9/62 ,  C07F9/65031 ,  C07F9/65522 ,  C07F9/650952 ,  C07F9/655345 ,  C07B2200/05 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2602/10 ,  C07C2603/74

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):




and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US11363815B2

公开(公告)日：2022-06-21

申请号：US16972042

申请日：2019-05-29

Applicant: SHENYANG UNIVERSITY OF CHEMICAL TECHNOLOGY

Inventor： Lixin Zhang ,  Jing Zhang ,  Po Zhang ,  Zhuo Kang

IPC: C07C323/42 ,  C07D209/46 ,  A01N43/38

Abstract: The present invention belongs to the field of agricultural acaricides, and particularly relates to a trifluoroethyl thioether (sulfoxide) substituted benzene compound and use thereof. The compound has a structure as shown in general formula I: The definition of each substituent in the formula is described in the specification. The compound of general formula I has excellent acaricidal activity and can be used to prevent and control various pest mites.

公开(公告)号：US20220143031A1

公开(公告)日：2022-05-12

申请号：US17520168

申请日：2021-11-05

Applicant: ALIGOS THERAPEUTICS, INC.

Inventor： David Craig McGowan ,  Pierre Jean-Marie Bernard Raboisson ,  Koen Vandyck ,  Jerome Deval ,  Leonid Beigelman

IPC: A61K31/53 ,  A61P1/16 ,  A61K31/404 ,  A61K31/437 ,  A61K31/575 ,  C07D209/96 ,  C07D403/12 ,  C07D413/12 ,  A61K31/451 ,  C07D471/04 ,  A61P3/04 ,  A61K31/46 ,  A61K31/506 ,  A61K31/4245 ,  C07D209/46

Abstract: Disclosed herein are compounds of Formula I′: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.

公开(公告)号：US20210371460A1

公开(公告)日：2021-12-02

申请号：US17149565

申请日：2021-01-14

Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education

Inventor： Peter Wipf ,  Marie-Celine Frantz

IPC: C07K5/08 ,  A61K31/454 ,  C07D211/58 ,  C07D401/12 ,  A61K47/64 ,  C07D417/12 ,  C07C237/16 ,  C07D209/46 ,  C07D211/94 ,  C07D221/22 ,  C07D209/44 ,  C07D279/06 ,  C07D471/08

Abstract: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation.

公开(公告)号：US20210194032A1

公开(公告)日：2021-06-24

申请号：US17177845

申请日：2021-02-17

Applicant: LOCKHEED MARTIN ENERGY, LLC

Inventor： Zachariah M. Norman ,  Matthew Millard ,  Emily Grace Nelson ,  Scott Thomas Humbarger

IPC: H01M8/18 ,  C07D209/04 ,  C07D209/46 ,  C07D221/00 ,  C07D279/12 ,  C07F1/00 ,  C07F3/00 ,  H01M4/36 ,  H01M4/60

Abstract: Flow batteries can include a first half-cell containing a first aqueous electrolyte solution, a second half-cell containing a second aqueous electrolyte solution, and a separator disposed between the first half-cell and the second half-cell, The first aqueous electrolyte solution contains a first redox-active material, and the second aqueous electrolyte solution contains a second redox-active material. At least one of the first redox-active material and the second redox-active material is a nitroxide compound or a salt thereof. Particular nitroxide compounds can include a doubly bonded oxygen contained in a ring bearing the nitroxide group, a doubly bonded oxygen appended to a ring bearing the nitroxide group, sulfate or phosphate groups appended to a ring bearing the nitroxide group, various heterocyclic rings bearing the nitroxide group, or acyclic nitroxide compounds.